Drugs / Ethanol
Ethanol
Trials 72 · started per year
today
1
2
2
2
1
6
3
2
2
2
4
3
4
4
8
3
5
4
1
1
1
1
4
4
1
199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT06659991 | May 2025 → Sep 2029 expected | temporomandibular joint disorder | University of Minnesota | Recruiting | No outcome recorded |
| Phase 0 | NCT06091189 | Feb 2024 → Feb 2025 | poisoning | Texas Tech University | Terminated | No outcome recorded |
| Phase 0 | NCT04669392 | Dec 2021 → Dec 2022 | abscess, pulpitis, root resorption | Cairo University | Unknown | No outcome recorded |
| Phase 0 | NCT05470972 | May 2020 → Nov 2021 | endometriosis | Tanta University | Completed | No outcome recorded |
| Phase 0 | NCT03964350 | May 2019 → Dec 2020 | alcohol-related disorders | University of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT03465917 | Mar 2018 → Mar 2019 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT03930446 | Jan 2016 → May 2019 | alcohol abuse | University of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT00616746 | Jan 2007 → Jun 2010 | alcohol-related disorders, nicotine dependence | Yale University | Completed | No outcome recorded |
| Phase 125 trials | ||||||
| Phase 1 | NCT07027839 | Dec 2025 → Feb 2028 expected | alcohol-related disorders | National Institute of Mental Health (NIMH) | Recruiting | No outcome recorded |
| Phase 1 | NCT06819189 | Jun 2025 → Dec 2027 expected | — | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Recruiting | No outcome recorded |
| Phase 1 | NCT05369065 | Jan 2022 → Jan 2025 overdue | hypertensive disorder, type 2 diabetes mellitus | Neurotronic, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT03294460 | Jun 2019 → Dec 2026 expected | alcohol-related disorders | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Recruiting | No outcome recorded |
| Phase 1 | NCT04166786 | May → Sep 2019 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT03257930 | Aug 2017 → Jul 2018 | nodular goiter | hassan harby mohamed | Completed | No outcome recorded |
| Phase 1 | NCT03010917 | Mar 2017 → May 2021 | alcohol dependence | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03165942 | Sep 2016 → Jun 2018 | alcohol abuse | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT02710331 | Mar 2016 → Dec 2026 expected | alcohol-induced mental disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02709954 | Mar 2016 → Dec 2026 expected | alcohol-induced mental disorder, cannabis dependence | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02710097 | Mar 2016 → Dec 2026 expected | alcohol-induced mental disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02404688 | Dec 2015 → Dec 2026 expected | alcohol-induced mental disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02213419 | Oct 2014 → Aug 2016 | pancreatic mucinous-cystic neoplasm | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT01865708 | Jul → Nov 2013 | — | Children's Healthcare of Atlanta | Completed | No outcome recorded |
| Phase 1 | NCT01590277 | Dec 2012 → Nov 2018 | alcohol-induced mental disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 1 | NCT01525706 | Sep 2012 → Nov 2016 | benign neoplasm of pancreas, pancreatic mucinous cystadenocarcinoma, pancreatic mucinous cystadenoma | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01578057 | Apr → Jun 2012 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01708369 | Feb → May 2012 | — | University of Tennessee | Completed | No outcome recorded |
| Phase 1 | NCT01375556 | May 2011 → Jan 2016 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Terminated | No outcome recorded |
| Phase 1 | NCT00713492 | Oct 2008 → Dec 2023 | alcohol-related disorders | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 1 | NCT00471679 | Apr 2007 → Feb 2010 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00437606 | Mar → Jun 2007 | type 2 diabetes mellitus | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00768183 | May → Jul 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02158039 | Jun 2004 → Sep 2015 | cystic, mucinous, and serous neoplasm | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02264145 | Nov → Dec 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/23 trials · 1 missed | ||||||
| Phase 1/2 | NCT02227329 | Jul 2014 → Oct 2016 | — | Mayo Clinic | Terminated | Missed primary |
| Phase 1/2 | NCT00299416 | Feb 2003 → Jan 2009 | ischemic stroke | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 1/2 | NCT01101412 | — | cancer of unknown primary site, infectious disease, leukemia, lymphoproliferative syndrome +3 | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06494891 | Jan 2024 → Apr 2027 expected | alcohol-related disorders | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 2 | NCT06118580 | Jun 2023 → Aug 2025 overdue | alcohol dependence, intermittent explosive disorder | Ohio State University | Recruiting | No outcome recorded |
| Phase 2 | NCT01539343 | Apr 2013 → Apr 2016 | infectious disease | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01263574 | Feb 2011 → Jun 2012 | prosthesis-related infectious disease, short bowel syndrome | Boston Children's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT00563342 | Jun 2007 → Mar 2008 | end stage renal failure | University Hospital, Clermont-Ferrand | Terminated | No outcome recorded |
| Phase 2 | NCT00462462 | May 2007 → Jun 2010 | congenital vascular malformation | Orfagen | Completed | No outcome recorded |
| Phase 2 | NCT00247585 | Sep 2003 → Jun 2006 | — | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06065657 | Feb 2024 → Dec 2025 overdue | alcohol-related disorders | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 37 trials · 1 met primary | ||||||
| Phase 3 | NCT06143059 | Jan 2024 → Aug 2028 | alcohol-related disorders | Ohio State University | Suspended | No outcome recorded |
| Phase 3 | NCT03083184 | Feb 2018 → Dec 2026 expected | — | University Hospital, Clermont-Ferrand | Recruiting | No outcome recorded |
| Phase 3 | NCT03253887 | Mar 2016 → Apr 2017 | infectious disease | Instituto Materno Infantil Prof. Fernando Figueira | Completed | No outcome recorded |
| Phase 3 | NCT02338297 | Feb 2016 → Feb 2017 | hepatocellular carcinoma | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT01898221 | Oct 2013 → Dec 2019 | atrial fibrillation, ventricular tachycardia | The Methodist Hospital Research Institute | Completed | Met primary |
| Phase 3 | NCT01186172 | Jun 2010 → Dec 2012 | bacterial infectious disease | Fondazione IRCCS Policlinico San Matteo di Pavia | Unknown | No outcome recorded |
| Phase 3 | NCT00680459 | May 2008 → Jun 2011 | infectious disease | Baystate Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 43 trials | ||||||
| Phase 4 | NCT02516150 | Mar 2016 → May 2017 | type 1 diabetes mellitus | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02095951 | Jun 2014 → Jun 2016 | cancer, leukemia, lymphoma | Children's Hospital of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT00666796 | Apr → May 2005 | insomnia | Viatris Inc. | Completed | No outcome recorded |
| Phase not applicable18 trials · 2 met primary · 1 missed | ||||||
| — | NCT07633509 | Jun 2026 → Dec 2028 expected | atrial fibrillation | Yunlong Wang | Not yet recruiting | No outcome recorded |
| — | NCT06865872 | Apr 2025 → Feb 2028 expected | alcohol-related disorders | University of Colorado, Denver | Recruiting | No outcome recorded |
| — | NCT04019093 | Nov 2019 → Apr 2022 | temporomandibular joint disorder | University of Florida | Completed | No outcome recorded |
| — | NCT04925076 | Nov 2018 → Jun 2023 | — | University of Florida | Completed | No outcome recorded |
| — | NCT03655717 | Nov 2018 → Jan 2021 | alcohol-related disorders, poisoning | Massachusetts General Hospital | Completed | Missed primary |
| — | NCT05953675 | Aug 2018 → Dec 2024 | — | Zealand University Hospital | Unknown | No outcome recorded |
| — | NCT03370783 | Mar → Sep 2017 | alcohol-related disorders | Brown University | Completed | No outcome recorded |
| — | NCT02472873 | Jun 2015 → Jun 2019 | ovarian endometriosis | Meir Medical Center | Unknown | No outcome recorded |
| — | NCT02515526 | Jun → Aug 2015 | — | University of Cologne | Completed | No outcome recorded |
| — | NCT02411331 | Mar 2015 → Jan 2017 | staphylococcal infection | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| — | NCT01974284 | Mar 2014 → Mar 2017 | thyroid gland papillary carcinoma | Yale University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01365312 | Feb 2010 → Jun 2011 | bacterial infectious disease, infectious disease with sepsis | East Carolina University | Terminated | No outcome recorded |
| — | NCT01229592 | Dec 2009 → Feb 2012 | prosthesis-related infectious disease | Hospital General Universitario Gregorio Marañon | Terminated | No outcome recorded |
| — | NCT00967421 | Sep → Nov 2009 | — | St. Olavs Hospital | Completed | Met primary |
| — | NCT00948441 | Aug 2008 → Dec 2014 | prosthesis-related infectious disease | University of Pittsburgh | Completed | Met primary |
| — | NCT00734656 | Mar 2007 → Oct 2010 | alcohol abuse, alcohol dependence | UConn Health | Completed | Mixed |
| — | NCT00284583 | May 2005 → ? | Morton neuroma | Brown University | Unknown | No outcome recorded |
| — | NCT00961792 | Mar 2004 → Sep 2026 overdue | alcohol dependence | University of Chicago | Active not recruiting | No outcome recorded |
| Comparator or background therapy23 trials | ||||||
| Phase 0 | NCT01814410 Comparator | Feb 2013 → Jun 2014 | — | Yale University | Completed | No outcome recorded |
| Phase 1/2 | NCT06906029 Comparator | Dec 2025 → Jul 2028 expected | abscess | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02577718 Background | Nov 2015 → Jun 2016 | nosocomial infection, prosthesis-related infectious disease | Novel Anti-Infective Technologies, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04584684 Comparator | Dec 2020 → Oct 2021 | COVID-19 | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2 | NCT02411175 Background | Oct 2014 → Aug 2015 | constipation disorder | University of Johannesburg | Completed | No outcome recorded |
| Phase 2 | NCT01475331 Comparator | Nov 2011 → Jan 2017 | pancreatic mucinous-cystic neoplasm | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT05268419 Comparator | Sep → Nov 2021 | infectious disease | Ali Amoushahi | Completed | No outcome recorded |
| Phase 3 | NCT04554433 Comparator | Dec 2020 → Oct 2021 | COVID-19 | Mansoura University | Unknown | No outcome recorded |
| Phase 3 | NCT03085004 Comparator | Apr 2019 → Dec 2025 | cystic tumor of the pancreas | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT01472965 Comparator | Dec 2011 → Nov 2016 | — | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06087588 Comparator | Oct 2023 → Jan 2025 | osteoarthritis, hip | Poznan University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT06087601 Comparator | Oct 2023 → Jan 2025 | osteoarthritis, knee | Poznan University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT04391660 Comparator | Jun 2020 → Jan 2021 | — | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03560193 Comparator | Sep 2018 → May 2022 | — | Poitiers University Hospital | Completed | Missed primary |
| Phase 4 | NCT00515151 Comparator | May 2002 → Apr 2005 | bacterial infectious disease, nosocomial infection | University Hospital Freiburg | Completed | No outcome recorded |
| — | NCT05291364 Background | Sep 2020 → Jun 2022 | — | Minia University | Completed | No outcome recorded |
| — | NCT02429219 Background | Nov 2013 → Feb 2015 | benign prostatic hyperplasia | University of Magdeburg | Completed | No outcome recorded |
| — | NCT01489410 Comparator | Oct 2012 → Mar 2014 | hepatocellular carcinoma | University of Minnesota | Withdrawn | No outcome recorded |
| — | NCT01996943 Comparator | Sep 2012 → May 2019 | alcohol-related disorders, atrial fibrillation | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT01257165 Comparator | Aug → Dec 2012 | — | St. Olavs Hospital | Withdrawn | No outcome recorded |
| — | NCT01350089 Comparator | Jan 2011 → May 2012 | alcohol-induced mental disorder | Medical University of Vienna | Unknown | No outcome recorded |
| — | NCT00764426 Comparator | Jun 2004 → ? | arteriosclerosis disorder, myocardial infarction | European Research Advisory Board | Completed | No outcome recorded |
| — | NCT00612352 Comparator | Mar 2001 → Jun 2015 | alcohol dependence | Yale University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-03-14 | CalciMedica, Inc. | Results CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology calcimedica.com ↗
CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the publication of a research paper describing how bile acid- and ethanol-mediated activation of Orai1 damages pancreatic ductal cells in AP. |
| 2016-02-26 | Palatin Technologies, Inc | Results Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Women’s Sexual Health Annual Meeting palatin.com ↗
The presentation concluded that, in a Phase 1 study, bremelanotide and ethanol can be safely co-administered and are generally well tolerated with no reports of drug-related serious adverse events. |
| 2008-07-01 | Alkermes, Inc. | Results Alkermes Presents Positive Data on Proprietary Molecules Targeting Opioid Receptors alkermes.com ↗
Data from two preclinical studies demonstrated that the three molecules showed statistically superior oral efficacy as well as evidence for improved metabolic and pharmacokinetic profiles compared to an active control. |
All press releases naming this drug 13 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 95 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ethanol | “Participants will receive intravenous alcohol (6% ethanol v/v in saline; obtained from the Ronald Reagan UCLA Medical Center Investigational Drug Service) over the course of an...” NCT06494891 ↗94“Recently, chemical renal denervation using ethanol (EtOH), was demonstrated to markedly lower blood pressure in small numbers of patients with resistant hypertension.” NCT03465917 ↗ “This study will test the reliability of a procedure for self-administering ethanol (alcohol) intravenously (through a vein), using a computer-assisted method.” NCT00713492 ↗ “with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline” NCT05291364 ↗ “Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter” NCT05369065 ↗ “Serial ethanol injection therapy has been reported to be an effective alternative to surgical excision.” NCT00284583 ↗ “The study lock solution is made up of minocycline, disodium ethylenediaminetetraacetate, and ethanol.” NCT01539343 ↗ “Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.” NCT00299416 ↗ “Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)” NCT02338297 ↗ “Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL” NCT00768183 ↗ “Mixture of 46.5 g ethanol (inform of vodka (37.5%))” NCT01350089 ↗ |
| Known as | Alcohol | “Participants will receive intravenous alcohol (6% ethanol v/v in saline; obtained from the Ronald Reagan UCLA Medical Center Investigational Drug Service) over the course of an...” NCT06494891 ↗8“For the next PET scan, participants will receive alcohol (ethanol) through a tube in a vein until they have a blood alcohol concentration that is equal to the legal driving limit.” NCT07027839 ↗ “This study will test the reliability of a procedure for self-administering ethanol (alcohol) intravenously (through a vein), using a computer-assisted method.” NCT00713492 ↗ “Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.” NCT04669392 ↗ “The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each.” NCT03930446 ↗ “Saline Irrigation with Ethanol (alcohol)” NCT02429219 ↗ “Drug: Alcohol (Ethanol)” NCT06865872 ↗ “Alcohol (Ethanol)” NCT06118580 ↗ “Alcohol (Ethanol)” NCT03294460 ↗ |
| Known as | Ethanol (EtOH) | “Ethanol (EtOH)” NCT02227329 ↗ |
| Known as | ethyl alcohol | “Medical grade ethyl alcohol (ethanol) is a widely used compound with uses as a disinfectant, preservative, antidote to ingested ethylene glycol (anti-freeze), and anti-microbial.” NCT01365312 ↗1“Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.” NCT04669392 ↗ |
| Known as | EtOH | “Recently, chemical renal denervation using ethanol (EtOH), was demonstrated to markedly lower blood pressure in small numbers of patients with resistant hypertension.” NCT03465917 ↗ |
| Known as | grain alcohol | “Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.” NCT04669392 ↗ |
| Action | Inhibit | “ethanol-mediated inhibition of carboxylesterases activity” NCT01708369 ↗ |
| Modality | Other / unclassified | “Ethanol is an inexpensive antiseptic agent” NCT03083184 ↗ |
| Route | Other | “Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.” NCT00299416 ↗ |